Aurobindo Pharma arm Acrotech Biopharma launches ADQUEY in US dermatology
Aurobindo Pharma’s Acrotech Biopharma has launched ADQUEY, a non-steroidal topical treatment for mild-to-moderate atopic dermatitis, in the US. The product enters a market estimated at around $1.3 billion for the 12 months ended July 2026, while Acrotech has established a dedicated dermatology business unit.
Source
